Clinical Trials Search Results

1 - 10 of 82 Results

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Read More

Pancreatic Cancer Neoadjuvant - Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

Combination Chemotherapy With or Without CyberKnife Before Surgery in Treating Patients With Pancreatic Cancer
Read More

Central Nervous System - Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Studying maintenance chemotherapy to see how well it works.

Read More

Acute Lymphoblastic Leukemia - Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Studies how well blinatumomab works compared with standard combination chemotherapy.

Read More

DLBCL Relapsed - A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Evaluates the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL or DLBCL.
Read More

Ewing's Sarcoma - Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Studies how well combination chemotherapy with or without ganitumab works in treating patients.

Read More

Heart Failure - Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Read More

ALK Positive NSCLC - Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Read More

HER2 Positive BC - Study of Tucatinib vs Placebo With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

 The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.

Learn more at Clinicaltrials.gov NCT02614794

Read More

EGFR Positive NSCLC - AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

To assess the efficacy and safety of AZD9291 versus Placebo.

Read More
1 - 10 of 82 Results